Egalet has entered into a definitive collaboration and pharma licensing deal with Shionogi for the development and potential commercialization of multiple oral abuse-deterrent hydrocodone opioid product candidates using Egalet's proprietary technology.
Egalet will receive a $10 million upfront payment from Shionogi.
In the pharma licensing deal, Shionogi has agreed to purchase up to approximately $15 million in common stock in a private placement to close concurrently with Egalet's recently filed initial public offering.
Egalet is eligible to receive milestone payments upon development and approval of products, which may exceed $300 million if multiple products are approved.
Shionogi will fund all costs associated with the development of these products.
Shionogi will also have exclusive global rights to commercialize the resulting products.
If any products developed under the collaboration are approved for marketing, Egalet is eligible to receive tiered royalties, ranging from the mid-single digits to the low double digits based on the net sales of such products.
As well as sales-based milestone payments that could exceed $100 million based on the attainment of specified sales thresholds.
Read the full article at Reuters (link no longer available)
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Shionogi
Report: Hepatitis Partnering
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity